赛升药业
(300485)
| 流通市值：37.49亿 | | | 总市值：65.94亿 |
| 流通股本：2.74亿 | | | 总股本：4.82亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 59,346,661.92 | 75,262,690.31 | 108,354,366.76 | 71,202,800.76 |
| 应收票据及应收账款 | 42,447,452.27 | 50,753,254.4 | 56,192,615.46 | 56,586,426.8 |
| 其中：应收票据 | 2,160,228.81 | 3,432,332.03 | 4,622,148.94 | 3,939,186.88 |
| 应收账款 | 40,287,223.46 | 47,320,922.37 | 51,570,466.52 | 52,647,239.92 |
| 预付款项 | 68,618.24 | 130,457.75 | 5,067,889.19 | 3,442,590.41 |
| 其他应收款合计 | 1,113,452.37 | 1,434,421.68 | 1,138,980.13 | 1,324,464.71 |
| 存货 | 85,650,658.49 | 81,369,540.32 | 90,176,588.5 | 96,454,934.63 |
| 其他流动资产 | 2,771,630.65 | 6,342,903.15 | 7,483,313.4 | 9,700,560.94 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,737,109,249.51 | 1,711,643,897.26 | 1,689,442,631.64 | 1,380,553,991.01 |
| 非流动资产: | | | | |
| 长期股权投资 | 722,277,531.66 | 706,402,153.78 | 719,908,754.18 | 727,607,596.6 |
| 其他非流动金融资产 | 254,958,480.3 | 251,480,159.97 | 256,028,164.26 | 545,824,849.47 |
| 固定资产 | 466,043,030.56 | 476,948,391.45 | 487,725,506 | 499,007,524.83 |
| 在建工程 | 11,045,073.7 | 11,032,073.7 | 1,432,758 | 1,368,958 |
| 生产性生物资产 | 7,163,659.21 | 7,007,245.01 | 6,855,694.35 | 5,952,222.24 |
| 使用权资产 | 11,606,032.45 | 11,693,735.5 | 11,846,627.69 | 11,934,817.19 |
| 无形资产 | 46,053,479.23 | 47,118,981.89 | 47,958,388.53 | 47,842,803.46 |
| 开发支出 | 296,826,233.56 | 292,706,479.2 | 261,169,533.79 | 247,949,367.61 |
| 商誉 | 21,865,087.82 | 21,865,087.82 | 21,865,087.82 | 21,865,087.82 |
| 递延所得税资产 | 1,524,946.44 | 1,787,957.56 | 2,335,461.73 | 2,354,056.75 |
| 其他非流动资产 | 11,987,251.62 | 12,162,402.33 | 11,211,840 | 11,402,880 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,851,350,806.55 | 1,840,204,668.21 | 1,828,337,816.35 | 2,123,110,163.97 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,588,460,056.06 | 3,551,848,565.47 | 3,517,780,447.99 | 3,503,664,154.98 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 12,321,372.08 | 15,724,458.8 | 11,490,298.25 | 11,108,129.77 |
| 应付账款 | 12,321,372.08 | 15,724,458.8 | 11,490,298.25 | 11,108,129.77 |
| 预收款项 | 352,293.58 | 352,293.58 | - | - |
| 合同负债 | 6,741,419.8 | 4,952,599.93 | 6,424,383.45 | 5,640,043.19 |
| 应付职工薪酬 | 4,682,155.09 | 5,270,864.15 | 4,540,678.48 | 4,549,988.27 |
| 应交税费 | 9,319,611.37 | 8,076,485.43 | 2,126,327.23 | 2,186,650.77 |
| 其他应付款合计 | 39,363,239.95 | 47,038,177.93 | 57,692,910.77 | 50,116,566.86 |
| 其他流动负债 | 876,384.57 | 639,432.14 | 835,169.85 | 733,205.61 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 73,656,476.44 | 82,054,311.96 | 83,109,768.03 | 74,334,584.47 |
| 非流动负债: | | | | |
| 递延收益 | 1,223,522.72 | 1,242,871.4 | - | - |
| 递延所得税负债 | 89,320,092.8 | 83,183,826.65 | 80,254,445.62 | 80,366,704.49 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 90,543,615.52 | 84,426,698.05 | 80,254,445.62 | 80,366,704.49 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 164,200,091.96 | 166,481,010.01 | 163,364,213.65 | 154,701,288.96 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 481,666,400 | 481,666,400 | 481,666,400 | 481,666,400 |
| 资本公积 | 845,927,046.31 | 845,927,046.31 | 845,927,046.31 | 845,927,046.31 |
| 其他综合收益 | 1,402,229.78 | 1,454,753.08 | 534,608.82 | 1,138,259.24 |
| 盈余公积 | 244,683,544.13 | 244,683,544.13 | 244,683,544.13 | 244,683,544.13 |
| 未分配利润 | 1,823,350,235.01 | 1,783,380,209.07 | 1,754,035,144.17 | 1,747,082,977.03 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,397,029,455.23 | 3,357,111,952.59 | 3,326,846,743.43 | 3,320,498,226.71 |
| 少数股东权益 | 27,230,508.87 | 28,255,602.87 | 27,569,490.91 | 28,464,639.31 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,424,259,964.1 | 3,385,367,555.46 | 3,354,416,234.34 | 3,348,962,866.02 |
| 负债和股东权益合计 | 3,588,460,056.06 | 3,551,848,565.47 | 3,517,780,447.99 | 3,503,664,154.98 |
| 公告日期 | 2025-04-24 | 2025-03-29 | 2024-10-25 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |